GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Net Interest Income (for Banks)

Elicera Therapeutics AB (OSTO:ELIC) Net Interest Income (for Banks)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Elicera Therapeutics AB (OSTO:ELIC) Business Description

Traded in Other Exchanges
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.